{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:45:59Z","timestamp":1795041959422,"version":"4.10.2"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.vaccine.2024.126692","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T22:09:01Z","timestamp":1736287741000},"page":"126692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease"],"prefix":"10.1016","volume":"47","author":[{"given":"Melike","family":"Yildirim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Keskinocak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hinderstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khang","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdani Basha Shaik","family":"Dasthagirisaheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Madoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Pelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inci","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vaccine.2024.126692_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2024.126692_bb0010","first-page":"6","volume":"7","author":"Briles","year":"2019","journal-title":"Pneumococcal Vaccines Microbiol Spectr"},{"key":"10.1016\/j.vaccine.2024.126692_bb0015","unstructured":"CDC. Clinical Overview of Pneumococcal Disease 2024 [November 13, 2024]. Available from: https:\/\/www.cdc.gov\/pneumococcal\/hcp\/clinical-overview\/index.html#:\u223c:text=Carriage%20of%20pneumococci&text=Adults%20without%20children:%205\u201310,50\u201360%25%20may%20be%20carriers."},{"issue":"4","key":"10.1016\/j.vaccine.2024.126692_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000327","article-title":"Factors associated with pneumococcal nasopharyngeal carriage: A systematic review","volume":"2","author":"Neal","year":"2022","journal-title":"PLOS Glob Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126692_bb0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.vaccine.2010.10.032","article-title":"Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease","volume":"29","author":"Yildirim","year":"2010","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2024.126692_bb0030","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1016\/j.vaccine.2017.05.077","article-title":"Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts\u2019 children to relatively low invasiveness","volume":"35","author":"Yildirim","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126692_bb0035","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1469-0691.2010.03183.x","article-title":"Streptococcus pneumoniae: virulence factors and variation","volume":"16","author":"Mitchell","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2024.126692_bb0040","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fimmu.2018.01366","article-title":"Streptococcus pneumoniae\u2019s Virulence and Host Immunity: Aging, Diagnostics, and Prevention","volume":"9","author":"Brooks","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126692_bb0045","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/21505594.2021.1889812","article-title":"Pathogenicity and virulence of Streptococcus pneumoniae: Cutting to the chase on proteases","volume":"12","author":"Marquart","year":"2021","journal-title":"Virulence"},{"key":"10.1016\/j.vaccine.2024.126692_bb0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/microbiolspec.GPP3-0019-2018","article-title":"Streptococcus pneumoniae Capsular Polysaccharide","volume":"7","author":"Paton","year":"2019","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126692_bb0055","first-page":"27","article-title":"A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens","volume":"21","author":"Daniels","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126692_bb0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1473-3099(22)00526-6","article-title":"Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1\/2, randomised, double-blind, active comparator-controlled, multicentre","volume":"23","author":"Platt","year":"2023","journal-title":"US-based trial Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126692_bb0065","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(23)00572-8","article-title":"Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1\/2, double-masked, dose-finding, active-controlled, randomised clinical trial","volume":"24","author":"Wassil","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126692_bb0070","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-0001","article-title":"Immunization, Antibiotic Use, and Pneumococcal Colonization Over a 15-Year Period","volume":"140","author":"Lee","year":"2017","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126692_bb0075","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1542\/peds.2014-2426","article-title":"Members of the Massachusetts Department of Public H. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease","volume":"135","author":"Yildirim","year":"2015","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126692_bb0080","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/INF.0b013e3182615615","article-title":"Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods","volume":"31","author":"Yildirim","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126692_bb0085","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.vaccine.2019.12.060","article-title":"Who is at risk of 13-valent conjugated pneumococcal vaccine failure?","volume":"38","author":"Yildirim","year":"2020","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126692_bb0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/jpids\/pit057","article-title":"Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts","volume":"3","author":"Lee","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126692_bb0095","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1542\/peds.2014-0473","article-title":"Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine","volume":"134","author":"Iroh Tam","year":"2014","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126692_bb0100","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1542\/peds.2004-2338","article-title":"Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004","volume":"116","author":"Huang","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2024.126692_bb0105","unstructured":"Massachusetts Births 2021 Boston, MA: Registry of Vital Records and Statistics, Massachusetts Department of Public Health. July 2023. [Available from: https:\/\/www.mass.gov\/doc\/2021-birth-report\/download."},{"key":"10.1016\/j.vaccine.2024.126692_bb0110","unstructured":"Centers for Disease Control and Prevention. Vaccination Coverage among Young Children (0-35 months) Available from, 2024: https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/childvaxview\/interactive-reports\/index.html."},{"key":"10.1016\/j.vaccine.2024.126692_bb0115","series-title":"Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing","year":"2017"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126692_bb0120","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2008-3099","article-title":"Continued Impact of Pneumococcal Conjugate Vaccine on Carriage in Young Children","volume":"124","author":"Huang","year":"2009","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126692_bb0125","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1128\/JCM.02498-06","article-title":"Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA","volume":"45","author":"Carvalho Mda","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2024.126692_bb0130","series-title":"Encylopedia of Biostatistics","author":"Armitage","year":"2005"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126692_bb0135","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1038\/s41598-018-30345-5","article-title":"Longitudinal characterization of nasopharyngeal colonization with Streptococcus pneumoniae in a South African birth cohort post 13-valent pneumococcal conjugate vaccine implementation","volume":"8","author":"Dube","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126692_bb0140","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00018-12","article-title":"Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines","volume":"25","author":"Tan","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126692_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11061376","article-title":"Pneumococcal Serotype Evolution and Burden in European Adults in the Last Decade: A Systematic Review","volume":"11","author":"Teixeira","year":"2023","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126692_bb0150","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2214-109X(18)30422-4","article-title":"Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis","volume":"7","author":"Chen","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126692_bb0155","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126692_bb0160","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/cid\/ciab066","article-title":"Effectiveness of the 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-Serotype Otitis Media","volume":"73","author":"Dagan","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24013744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24013744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T03:15:18Z","timestamp":1739416518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24013744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"alternative-id":["S0264410X24013744"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126692","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126692"}}